The doctor-initiated study will be conducted with one patient with aplastic anemia with platelet transfusion failure complication. Production of platelets are done from the patient’s (autologous) iPS cells through megakaryocyte cells, a method developed by Hiroyuki ETO of CiRA. In his method, hematopoietic progenitor cells are induced from iPS cells and in a complex procedure differentiated into megakaryocyte cells who are frozen and stored as a master cell bank (MCB).

Nikkei Biotech news release, September 25, 2019